Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis

被引：12

作者：

Gao, Weiqi ^{[1
]}

Zeng, Yufei ^{[1
]}

Fei, Xiaochun ^{[2
]}

Chen, Xiaosong ^{[1
]}

Shen, Kunwei ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg,Comprehens Breast Hlth Ctr, 197 Ruijin Second Rd, Shanghai 200025, Peoples R China

[2] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pathol, Shanghai 200025, Peoples R China

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2020年 / 184卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Adjuvant treatment; Axillary lymph node dissection; Breast cancer; Histological special type; Non-sentinel lymph node metastasis; Prognosis; BIOPSY; DISSECTION; CRITERIA; WOMEN;

D O I：

10.1007/s10549-020-05842-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Given the histological special types (HST) of breast carcinoma accounted for minority of the Z0011 study population, this study aimed to assess the rates of axillary lymph node (ALN) involvement and non-sentinel lymph node (SLN) metastasis in patients with invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), or other HST. Methods Patients with cT1-2N0M0 breast cancer treated between 2009 and 2018 were retrospectively included from a multi-institutional database. Rates of nodal involvement were analyzed among different histological subgroups. The impact of ALN dissection (ALND) on adjuvant treatment decisions and prognosis were also analyzed among patients with 1-2 + SLNs. Results A total of 8294 patients were included: 6854 (82.6%), 257 (3.1%), and 1183 (14.3%) patients with IDC, ILC, and other HST, respectively. IDC patients had a significantly higher rate of ALN metastasis compared with ILC or other HST (31.9% vs. 22.6% vs. 16.4%,P < 0.001). However, in patients with 1-2 + SLNs, rates of non-SLN metastasis were similar among three groups (IDC:n = 182, 28.6% vs. ILC:n = 5, 31.2% vs. other HST:n = 29, 34.9%, P = 0.481). For patients with 1-2 + SLNs, rates of adjuvant chemotherapy and the estimated 3-year recurrence-free survival were similar between the SLN biopsy and ALND arms, regardless of the histological types. Conclusion Among patients with 1-2 + SLNs, ILC or other HST had similar rates of non-SLN metastasis compared with IDC. Omission of ALND may not influence adjuvant chemotherapy usage or disease outcome regardless of histological types.

引用

页码：193 / 202

页数：10

共 21 条

[1] Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma [J].

Adachi, Yayoi ;

Sawaki, Masataka ;

Hattori, Masaya ;

Yoshimura, Akiyo ;

Gondo, Noami ;

Kotani, Haruru ;

Iwase, Madoka ;

Kataoka, Ayumi ;

Onishi, Sakura ;

Sugino, Kayoko ;

Terada, Mitsuo ;

Horisawa, Nanae ;

Mori, Makiko ;

Oze, Isao ;

Iwata, Hiroji .

BREAST CANCER, 2018, 25 (05) :560-565

[2] Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers [J].

Corona, S. P. ;

Bortul, M. ;

Scomersi, S. ;

Bigal, C. ;

Bottin, C. ;

Zanconati, F. ;

Fox, S. B. ;

Giudici, F. ;

Generali, D. .

BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) :735-745

[3] Sentinel lymph node biopsy and non-sentinel node involvement in special type breast carcinomas with a good prognosis [J].

Cserni, Gabor ;

Bianchi, Simonetta ;

Vezzosi, Vania ;

Arisio, Riccardo ;

Bori, Rita ;

Peterse, Johannes L. ;

Sapino, Anna ;

Drijkoningen, Maria ;

Kulka, Janina ;

Eusebi, Vincenzo ;

Foschini, Maria Pia ;

Bellocq, Jean-Pierre ;

Marin, Cristi ;

Thorstenson, Sten ;

Amendoeira, Isabel ;

Reiner-Concin, Angelika ;

Decker, Thomas .

EUROPEAN JOURNAL OF CANCER, 2007, 43 (09) :1407-1414

[4] Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy [J].

Dengel, Lynn T. ;

Van Zee, Kimberly J. ;

King, Tari A. ;

Stempel, Michelle ;

Cody, Hiram S. ;

El-Tamer, Mahmoud ;

Gemignani, Mary L. ;

Sclafani, Lisa M. ;

Sacchini, Virgilio S. ;

Heerdt, Alexandra S. ;

Plitas, George ;

Junqueira, Manuela ;

Capko, Deborah ;

Patil, Sujata ;

Morrow, Monica .

ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (01) :22-27

[5] Is completion axillary lymph node dissection necessary in patients who are underrepresented in the ACOSOG Z0011 trial? [J].

Gebhardt, Brian J. ;

Thomas, Joel ;

Horne, Zachary D. ;

Champ, Colin E. ;

Farrugia, Daniel J. ;

Diego, Emilia ;

Ahrendt, Gretchen M. ;

Beriwal, Sushil .

ADVANCES IN RADIATION ONCOLOGY, 2018, 3 (03) :258-264

[6] Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial [J].

Giuliano, Armando E. ;

Ballman, Karla V. ;

McCall, Linda ;

Beitsch, Peter D. ;

Brennan, Meghan B. ;

Kelemen, Pond R. ;

Ollila, David W. ;

Hansen, Nora M. ;

Whitworth, Pat W. ;

Blumencranz, Peter W. ;

Leitch, A. Marilyn ;

Saha, Sukamal ;

Hunt, Kelly K. ;

Morrow, Monica .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (10) :918-926

[7] Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial [J].

Giuliano, Armando E. ;

Ballman, Karla ;

McCall, Linda ;

Beitsch, Peter ;

Whitworth, Pat W. ;

Blumencranz, Peter ;

Leitch, A. Marilyn ;

Saha, Sukamal ;

Morrow, Monica ;

Hunt, Kelly K. .

ANNALS OF SURGERY, 2016, 264 (03) :413-420

[8] Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis A Randomized Clinical Trial [J].

Giuliano, Armando E. ;

Hunt, Kelly K. ;

Ballman, Karla V. ;

Beitsch, Peter D. ;

Whitworth, Pat W. ;

Blumencranz, Peter W. ;

Leitch, A. Marilyn ;

Saha, Sukamal ;

McCall, Linda M. ;

Morrow, Monica .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (06) :569-575

[9] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J].

Goldhirsch, A. ;

Winer, E. P. ;

Coates, A. S. ;

Gelber, R. D. ;

Piccart-Gebhart, M. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2013, 24 (09) :2206-2223

[10] Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) [J].

Gourgou-Bourgade, S. ;

Cameron, D. ;

Poortmans, P. ;

Asselain, B. ;

Azria, D. ;

Cardoso, F. ;

A'Hern, R. ;

Bliss, J. ;

Bogaerts, J. ;

Bonnefoi, H. ;

Brain, E. ;

Cardoso, M. J. ;

Chibaudel, B. ;

Coleman, R. ;

Cufer, T. ;

Dal Lago, L. ;

Dalenc, F. ;

De Azambuja, E. ;

Debled, M. ;

Delaloge, S. ;

Filleron, T. ;

Gligorov, J. ;

Gutowski, M. ;

Jacot, W. ;

Kirkove, C. ;

MacGrogan, G. ;

Michiels, S. ;

Negreiros, I. ;

Offersen, B. V. ;

Llorca, F. Penault ;

Pruneri, G. ;

Roche, H. ;

Russell, N. S. ;

Schmitt, F. ;

Servent, V. ;

Thuerlimann, B. ;

Untch, M. ;

van der Hage, J. A. ;

van Tienhoven, G. ;

Wildiers, H. ;

Yarnold, J. ;

Bonnetain, F. ;

Mathoulin-Pelissier, S. ;

Bellera, C. ;

Dabakuyo-Yonli, T. S. .

ANNALS OF ONCOLOGY, 2015, 26 (05) :873-879

← 1 2 3 →